Concord Biotech Ltd. (IN:CONCORDBIO)
:CONCORDBIO
Want to see IN:CONCORDBIO full AI Analyst Report?
CONCORDBIO Stock Chart & Stats
₹1338.60
₹62.10(2.74%)
At close: 4:00 PM EST
₹1338.60
₹62.10(2.74%)
Day’s Range― - ―
52-Week Range₹987.05 - ₹2,149.90
Previous CloseN/A
Volume295.44K
Average Volume (3M)12.81K
Market Cap
₹138.81B
Enterprise Value₹109.86B
Total Cash (Recent Filing)₹3.81B
Total Debt (Recent Filing)₹16.07M
Price to Earnings (P/E)53.6
Beta1.09
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)30.92
Shares Outstanding104,616,200
10 Day Avg. Volume31,605
30 Day Avg. Volume12,808
Financial Highlights & Ratios
PEG Ratio-1.36
Price to Book (P/B)5.32
Price to Sales (P/S)10.16
P/FCF Ratio61.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)36.7
Revenue Forecast (FY)₹13.05B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and steadily rising equity reduce financial risk and preserve optionality. Over the medium term this supports durable investment in capacity or R&D, sustains operations through demand cycles, and lowers refinancing and bankruptcy risk versus peers.
Consistent Operating Cash GenerationOperating cash flow that consistently exceeds net income indicates solid earnings quality and internal funding capacity. Rebounding FCF in 2026 demonstrates the business can recover cash conversion, supporting capital expenditures, working capital needs, and shareholder returns over the next several quarters.
Specialized Fermentation API CapabilityComplex fermentation-based APIs create technical barriers and customer stickiness. Specialized process know-how and scale-intensive manufacturing support pricing power, long-term contracts and limited competition, forming a durable competitive advantage in supply of difficult-to-make APIs.
Bears Say
Recent Revenue DeclineA material top-line contraction interrupts prior growth momentum and reduces visibility for medium-term planning. If demand softness persists, the company may face underutilized capacity and weaker negotiation leverage with customers, affecting sustainable growth prospects.
Margin Compression And Earnings NormalizationCompression from peak margins and stepped-down net income suggest either cost pressures or waning pricing power. Sustained margin pressure would erode return on invested capital, limit reinvestment and reduce the firm's ability to finance strategic initiatives internally.
Volatile Free Cash Flow HistoryIntermittent negative FCF and swings indicate sensitivity to reinvestment cycles or working-capital swings. That volatility complicates consistent capital allocation, may force occasional external financing, and increases execution risk during downturns or when funding strategic projects.
Concord Biotech Ltd. News
CONCORDBIO FAQ
What was Concord Biotech Ltd.’s price range in the past 12 months?
Concord Biotech Ltd. lowest stock price was ₹987.05 and its highest was ₹2149.90 in the past 12 months.
What is Concord Biotech Ltd.’s market cap?
Concord Biotech Ltd.’s market cap is ₹138.81B.
When is Concord Biotech Ltd.’s upcoming earnings report date?
Concord Biotech Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 56 days.
How were Concord Biotech Ltd.’s earnings last quarter?
Concord Biotech Ltd. released its earnings results on May 29, 2026. The company reported ₹8.5 earnings per share for the quarter, missing the consensus estimate of ₹8.9 by -₹0.4.
Is Concord Biotech Ltd. overvalued?
According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued.
Does Concord Biotech Ltd. pay dividends?
Concord Biotech Ltd. pays a Notavailable dividend of ₹7.55 which represents an annual dividend yield of 0.8%. See more information on Concord Biotech Ltd. dividends here
What is Concord Biotech Ltd.’s EPS estimate?
Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Biotech Ltd. have?
Concord Biotech Ltd. has 104,616,200 shares outstanding.
What happened to Concord Biotech Ltd.’s price movement after its last earnings report?
Concord Biotech Ltd. reported an EPS of ₹8.5 in its last earnings report, missing expectations of ₹8.9. Following the earnings report the stock price went down -4.598%.
Which hedge fund is a major shareholder of Concord Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:CONCORDBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Biotech Ltd.
Established in 1984 and headquartered in Ahmedabad, India, Concord Biotech Limited operates as a biopharmaceutical enterprise focused on the discovery, development, production, and global commercialization of pharmaceutical goods. A core component of its offerings comprises fermentation-derived active pharmaceutical ingredients (APIs) applied across various critical medical fields. These include immunosuppressive agents (such as tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus), anti-bacterial compounds (like mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin), oncology treatments (including temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin), and antifungal medications (such as anidulafungin, caspofungi, and micafungin sodium). Additionally, the company supplies other specialized APIs like lovastatin and pravastatin sodium. Concord Biotech further augments its services by providing contract research and manufacturing solutions (CRAMS), particularly emphasizing fermentation and semi-synthesis capabilities.
Technical Analysis
Biocon Limited
―
Blue Jet Healthcare Limited
―
Jubilant Ingrevia Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―